# BRIA-ABC (NCT06072612)

> Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06072612
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: BriaCell Therapeutics Corporation
- Conditions: Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm; Breast Cancer Metastatic; End Stage Cancer
- Interventions: SV-BR-1-GM; Cyclophosphamide; Interferon infiltration of the inoculation site; Retifanlimab; Treatment of Physician's Choice
- Enrollment: 404
- Primary outcome: Overall Survival

## Indexed commentary on BRIA-ABC so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bria-abc-nct06072612
